MedPath
Found 5 clinical trials|View Analysis
Sort by:

Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

Phase 3
Not yet recruiting
Conditions
Type 2 Diabetic Nephropathy
Interventions
Drug: DWP16001 Placebo
Drug: DWP16001 0.3mg
First Posted Date
2024-09-20
Last Posted Date
2024-09-20
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
348
Registration Number
NCT06606093
Locations
🇰🇷

Korea university ansan hospital, Ansan, Gyeongggi-do, Korea, Republic of

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Phase 3
Active, not recruiting
Conditions
Diabetes Mellitus, Type 2
Metabolic Disease
Diabetes Mellitus
Glucose Metabolism Disorders
Endocrine System Diseases
Interventions
Drug: DWP16001
Drug: Dapagliflozin
Drug: Dapagliflozin Placebo
Drug: DWP16001 Placebo
First Posted Date
2022-08-18
Last Posted Date
2024-04-04
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
340
Registration Number
NCT05505994
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Phase 3
Recruiting
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: DWP16001 0.3mg
Drug: DWP16001 Placebo
First Posted Date
2022-07-20
Last Posted Date
2024-04-08
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
240
Registration Number
NCT05466643
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.

Phase 3
Completed
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Drug: DWP16001 Amg
First Posted Date
2022-05-17
Last Posted Date
2022-10-25
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
63
Registration Number
NCT05376930
Locations
🇰🇷

Daewoong pharmatceutical, Seoul, Korea, Republic of

The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.

Phase 3
Completed
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Drug: DWP16001
First Posted Date
2020-11-17
Last Posted Date
2022-10-25
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
140
Registration Number
NCT04632862
Locations
🇰🇷

Daewoong pharmatceutical, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath